KCRS25 Program
All times are in EDT
Thursday, July 17th
Registration and Continental Breakfast
Pre-meeting: Variant Kidney Cancers: Bridging Biology to Breakthroughs
Moderated by
Rana McKay, University of California, San Diego & Ari Hakimi, Memorial Sloan Kettering Cancer Center
PRE-MEETING SESSION 1
Biology and Therapeutic Vulnerabilities: Needs and Opportunities
Variant 1: Papillary
Bradley McGregor, Dana-Farber Cancer Institute
Variant 2: Chromophobe
Elizabeth Henske, Brigham and Women’s Hospital/Harvard Medical School
Variant 3: Translocation
Srinivas Viswanathan, Dana-Farber Cancer Institute
Variant 4: Unclassified
Yingbei Chen, Memorial Sloan Kettering Cancer Center
Moderated Panel Discussion on Needs and Opportunities in Developing Mechanistic Information on Vulnerabilities and Existing Drugs
Break
PRE-MEETING SESSION 2
Clinical Trial Design and Execution
Lessons Learned from Other Cancers
Vivek Subbiah, Sarah Cannon Research Institute
Statistical Approaches for Designing and Conducting Rare Subtype Trials
Wanling Xie, Dana-Farber Cancer Institute
Regulatory Considerations and Endpoints for Rare Subtype Trials
Chana Weinstock, U.S. Food and Drug Administration
Patient Advocacy, Registry, and Trial Recruitment: What Has Worked in Rare Cancers
Joshua Mann, VHL Alliance
Industry Support of Rare Subtype Trials
Sumanta Pal, City of Hope Comprehensive Cancer Center
Moderated Panel Discussion on Moving the Needle on Trial Design for Rare and Variant Subtypes
KCRS Welcome & Introductions
Bryan Lewis, KidneyCAN CEO
Keynote: Leading the Way in Fostering Early Careers with a Focus on Kidney Cancer
W. Kimryn Rathmell, The Ohio State University Comprehensive Cancer Center
Session 1
From Federal Funding to Patient Impact: Kidney Cancer Research That Delivers
Moderated by
Eric Jonasch, MD Anderson Cancer Center
Cheryl Walker, Baylor College of Medicine
Building the Infrastructure for Discovery: A Clinical Trial Consortium to Accelerate Kidney Cancer Research
Eric Jonasch, MD Anderson Cancer Center
Personalized Vaccines in Kidney Cancer: A Journey from Concept to Clinic
David Braun, Yale School of Medicine
Targeting Ferroptosis in Clear Cell RCC: Translating KCRP Discoveries into the Clinic
Mei Koh, University of Utah
From Bench to Bedside: Advancing KIM-1 as a Tool for Clinical Decision-Making
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
Redesigning CAR-T for Solid Tumors: A New Path Toward Cures for Kidney Cancer
Wayne Marasco, Dana-Farber Cancer Institute
Moderated Panel Discussion on Earmarked Research Funding and the Future of Kidney Cancer
Cheryl Walker, Baylor College of Medicine
Lunch and Networking
Session 2
Charting the Next Frontier: Genetic Evaluation and Screening for Early Detection of Kidney Cancer
Moderated by
Michael Serzan, Dana-Farber Cancer Institute
Samantha Greenberg, UT Southwestern Medical Center
The State of Screening Individuals with a Hereditary Risk of Kidney Cancer
Maria Carlo, Memorial Sloan Kettering Cancer Center
Novel Imaging Approaches for Early Detection of Kidney Cancer
Mark Ball, National Cancer Institute
A Genetic Perspective: Optimizing Screening for Individuals with Negative Germline Testing
Lindsey Byrne, The Ohio State University Comprehensive Cancer Center
Risk Stratified Screening for Kidney Cancer
Grant Stewart, University of Cambridge
Session 3
Trials in Progress
Moderated by
Robert Motzer, Memorial Sloan Kettering Cancer Center
Thai Ho, Medical University of South Carolina
Phase II Trial of Ivonescimab in Patients with Advanced Clear Cell Renal Cell Carcinoma Previously Treated with Immune Checkpoint Blockade: IVORY Trial (NCT06940518)
Nazli Dizman, MD Anderson Cancer Center
A Phase 1, Multiple-Dose Study to Evaluate the Safety and Tolerability of First-in-Class XmAb819 (ENPP3 x CD3) in Subjects with Relapsed or Refractory Clear Cell Renal Cell Carcinoma (ccRCC) (NCT05433142)
Ritesh Kotecha, Memorial Sloan Kettering Cancer Center
Short TeRm Intensified Pembrolizumab (KEytruda) and Tivozanib for High-Risk Renal Cell Carcinoma – STRIKE! (A033201) – (NCT06661720)
Bradley McGregor, Dana-Farber Cancer Institute
LASER – a Phase 2 trial of 177Lu-PSMA-617 as Systemic Therapy for Renal Cell Carcinoma (NCT06964958)
Praful Ravi, Dana-Farber Cancer Institute
EXACT: A Randomized Phase II Trial of XL092 (Zanzalintinib) in Combination with Immunotherapy in Patients who Progress on Adjuvant Therapy in Clear Cell RCC (NCT06863311)
Karie Runcie, Columbia University Irving Medical Center
A Phase 0 Pilot Study of Memory-like Natural Killer (NK) Cell Immune Therapy in Patients with Renal Cell Carcinoma or Urothelial Carcinoma (NCT06318871)
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
Q&A Discussion – Moving the Needle Forward
Afternoon Break
International Neoadjuvant Kidney Cancer Consortium: First Year Report
Axel Bex, Netherlands Cancer Institute
Grant Stewart, University of Cambridge
Session 4
Rapid Oral Abstract Presentations
Moderated by
Sumanta Pal, City of Hope Comprehensive Cancer Center
Kelly Fitzgerald, University of California, San Francisco
Quality-Adjusted Time without Symptoms or Toxicity (Q-TWiST) Analysis of Belzutifan Versus Everolimus in Previously Treated Advanced Renal Cell Carcinoma (RCC): LITESPARK-005 (LS-005)
Thomas Powles, Barts Cancer Center
Exploring Health-Related Quality of Life Across the Disease Spectrum in Renal Cell Carcinoma: A Conceptual Domain Analysis
Koral Shah, City of Hope Comprehensive Cancer Center
Phase 2 Trial of Metastasis Directed Radiotherapy Without Systemic Therapy (MRWS) for Oligometastatic Clear Cell Renal Cell Carcinoma (ccRCC) and Investigation of Circulating Tumor DNA (ctDNA)
Chad Tang, MD Anderson Cancer Center
The Actionable Microbial Gut Checkpoint MAdCAM-1 in Patients with Advanced Renal Cell Carcinoma
Carolina Alves Costa Silva, Institut Gustave Roussy
Characterizing Carbonic Anhydrase 9 and HIF-2α RNA Expression in Clear Cell Renal Cell Carcinoma (ccRCC)
Yu-Wei Chen, University of California, San Diego
Influence of Sex on Immunosurveillance and Metastatic Tropism in Novel Mouse Models of Clear Cell Renal Cell Carcinoma
Doris Zheng, Memorial Sloan Kettering Cancer Center
Evaluating Global Disparities in Clinical Trial Availability for Renal Cell Carcinoma
Ruchi Agarwal, University of Pennsylvania
Investigating the Mechanisms of Neoadjuvant Olaparib and Cediranib in Renal Cancer: Results of Arms 1 to 3 of the WIndow of Opportunity in REnal cancer (WIRE) Clinical Trial
James Jones, University of Cambridge
Real-World Evidence Shows No Survival Advantage with Contemporary First-Line Strategies in Papillary Renal Cell Carcinoma: A Call for Randomized Trials
Miguel Zugman, City of Hope Comprehensive Cancer Center
Awards Announcement
Bryan Lewis, KidneyCAN CEO
Posters and Prosecco
Reception at Matria
KINDLY SPONSORED BY
Rock the Run in Boston will take place at sunrise on the second day of the Kidney Cancer Research Summit. All KCRS registrants will receive a Rock the Run t-shirt and are invited to participate in this 5k. Rock the Run is a fun, no-pressure event! You can join us to walk, run, or cheer and spectate.
Register as an individual, or join one of our teams captained by some of the best kidney cancer researchers in the world!
Your support can help accelerate cures for kidney cancer!
Friday, July 18th
Rock the Run 5K
Registration and Breakfast
Welcome & Introductions
Bryan Lewis, KidneyCAN CEO
Founding Partner Presentation
The Road to Non-Clear Cell RCC
Jose Perez Torrealba, Exelixis
Session 5
Clinical and Scientific Updates in Kidney Cancer
Moderated by
Toni Choueiri, Dana-Farber Cancer Institute
Front Line Systemic Therapy Strategies
David McDermott, Beth Israel Deaconess Medical Center
Subsequent Line Treatments for Advanced Disease
Robert Motzer, Memorial Sloan Kettering Cancer Center
Adjuvant Treatment Options
Naomi Haas, Abramson Cancer Center
Strategies for Patients with Rare Subtypes
Mehmet Bilen, Emory Winship Cancer Institute
Novel Therapies Outside Immunotherapy
Thai Ho, Medical University of South Carolina
Essential Biomarkers in RCC
Wenxin (Vincent) Xu, Dana-Farber Cancer Institute
Coffee Break – Friends of KidneyCAN Networking in Eleanor/Dartmouth Room
Session 6
From Concept to Clinic: The Emerging Role of Precision Immunotherapy in Kidney Cancer
Moderated by
Hans Hammers, UT Southwestern Medical Center
David Braun, Yale School of Medicine
Engaging Native Immunity through ENPP3
Charles Drake, Johnson & Johnson
Novel Targets for Cellular Therapies in RCC
Rosa Nadal Rios, Fred Hutchinson Cancer Center
Next Generation T-Cell Engineering
Sidi Chen, Yale School of Medicine
Future of Cancer Vaccines
Patrick Ott, Dana-Farber Cancer Institute
Moderated Panel Discussion on “Dream Trials”
Lunch and Networking
Session 7
Oral Abstract Presentations
Moderated by
Rana McKay, University of California, San Diego
Wesley Yip, City of Hope Comprehensive Cancer Center
Combination Casdatifan plus Cabozantinib in Previously Treated Patients with Clear Cell Renal Cell Carcinoma: Results from an Expansion Cohort of ARC-20 (NCT05536141)
Toni Choueiri, Dana-Farber Cancer Institute
Pembrolizumab Plus Lenvatinib for Previously Untreated Advanced Non–Clear Cell Renal Cell Carcinoma: 3-Year Follow-up of the Phase 2 KEYNOTE-B61 Study
Laurence Albiges, Institut Gustave Roussy
CD163⁺ Tumor-Associated Macrophages and Clinical Outcomes to First-Line Nivolumab Therapy in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Insights from the HCRN GU16-260 Trial
Berkay Simsek, Brigham and Women’s Hospital
Integrative Clinical, Genomic, Transcriptomic, and Immunopathologic Characterization of Circulating KIM-1 in Metastatic RCC
Marc Machaalani, Dana-Farber Cancer Institute
Lower Checkpoint Gene Expression is Associated with Primary Resistance to Nivolumab-Ipilimumab Combination in Advanced Renal Cell Carcinoma
Rana McKay, University of California, San Diego
Derepression of Human Endogenous Retroviruses in ccRCC: Implications for Immunotherapy
Qinqin Jiang, Dana-Farber Cancer Institute
Afternoon Break
Session 8
Biotech Showcase
Moderated by
Thomas Powles, Barts Cancer Centre
David McDermott, Beth Israel Deaconess Medical Center
Overcoming Innate and Adaptive Resistance in RCC: Combination with the Next-Generation Farnesyl Transferase Inhibitor, KO-2806, as a Strategy to Enhance VEGF TKI Efficacy
Jabed Seraj, Kura Oncology
Unmasking the Potential of Conditionally-Activated Cytokines: Lessons Learned from the Early Clinical Development of WTX-124, a Tumor-Activated IL-2 INDUKINE Molecule
Randi Isaacs, Werewolf Therapeutics
At the PEAK of ccRCC, HIF2a Drug Development eVOLVEs – Casdatifan Initiating Phase 3 Trials
Jonathan Yingling, Arcus Biosciences
ITM’s Investigational CAIX-targeted Radiopharmaceuticals for Diagnosis and Treatment of Patients with ccRCC: Ph I/II Trial Design and First-in-Human CAIX Images
Robert Awadallah, ITM Isotope Technologies
Targeting PTPN2/1 with ABV-CLS-484 as a Novel Immunotherapeutic Approach for Treating Cancer
Jonathan Powell, Calico Labs
Natera’s Portfolio for Ultrasensitive Molecular Residual Disease (MRD) Detection
Minetta Liu, Natera
Comprehensive Molecular Testing for Solid Tumors
Brian Liu, Caris Life Sciences
KCRS25 Closing
Bryan Lewis, KidneyCAN CEO
Thank You to the KCRS26 Partners & Sponsors
The Kidney Cancer Research Summit is funded through contributions from both grassroots donors and industry partners. We thank the generous partners and sponsors who support us in our mission to accelerate cures for kidney cancer.
Founding Partner
Sustaining Partners
Research Sponsors
Community Sponsors
Friends of KidneyCAN
